$11.42
Value $103M
ICCC and LLY stock compared: price, dividend, valuation and results, from SEC filings.
$11.42
Value $103M
$1,431.67
Value $1.35T
ImmuCell (ICCC) has a market value of $103M and Eli Lilly and Company (LLY) $1.35T. Over the last year, with dividends, ICCC moved +111.5% and LLY +40.5%. The P/E is 55.0 for ICCC and 49.0 for LLY. Dividend yield: ICCC none, LLY 0.44%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ICCC$103M
LLY$1.35T
LLY is 13,072 times ICCC
Revenue, 12 months
ICCC$33M
LLY$86.5B
LLY is 2,604 times ICCC
Net income, 12 months
ICCC$1.9M
LLY$27.6B
LLY is 14,673 times ICCC
Operating margin
ICCC14.5%
LLY–
ROIC
ICCC9.8%
LLY35.5%
25.7 points apart
P/E
ICCC55.0
LLY49.0
ICCC is 1.1 times LLY
Dividend yield
ICCC0.0%
LLY0.4%
0.4 points apart
5-year return
ICCC+24.1%
LLY+478.4%
454.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ICCC+24.1%
LLY+478.4%
| Period | ICCCWith dividends | LLYWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +111.5%Price +111.5% | +40.5%Price +39.6% |
| 3 years since November 16, 2023 | +143.0%+34.4% a yearPrice +143.0% | +148.1%+35.4% a yearPrice +143.2% |
| 5 years since November 15, 2021 | +24.1%+4.4% a yearPrice +24.1% | +478.4%+42.1% a yearPrice +454.0% |
| 10 years since November 16, 2016 | +133.1%+8.8% a yearPrice +133.1% | +2,064.5%+36.0% a yearPrice +1,760.8% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ICCCImmuCellLLYEli Lilly and Company
| Price | $11.42 | $1,431.67 |
|---|---|---|
| Market value | $103M | $1.35T |
| Enterprise value (EV) | $103M | $1.40T |
| P/E | 55.0 | 49.0 |
| P/E, 5-year median | – | 49.9 |
| P/B | 3.2 | 33.5 |
| EV/EBIT | 21.5 | 40.1 |
| Free cash flow yield | 5.2% | 1.5% |
| Revenue, 12 months | $33M | $86.5B |
|---|---|---|
| Net income, 12 months | $1.9M | $27.6B |
| Free cash flow, 12 months | $5.4M | $19.7B |
| Earnings per share, 12 months | $0.19 | $30.81 |
| Revenue growth, year on year | 4.3% | 44.7% |
| Revenue growth a year, past | +12.5%over 5 years | +21.6%over 5 years |
| EPS growth a year, past | – | +27.6%over 5 years |
| Gross margin | 40.8% | 83.6% |
|---|---|---|
| Operating margin | 14.5% | – |
| Net margin | 5.7% | 31.9% |
| ROIC | 9.8% | 35.5% |
| ROE | 6.3% | 88.6% |
| Cash | $7.9M | $4.9B |
|---|---|---|
| Total debt | $12M | $49.5B |
| Net debt / EBITDA | 0.0 | 1.2 |
| Interest cover | 12.2× | 38.9× |
| Dividend yield | – | 0.4% |
|---|---|---|
| Dividend per share, 12 months | – | $6.34 |
| Dividend growth a year, past | – | +15.2%over 5 years |
| Buyback yield | – | 0.3% |
| Shareholder yield | – | 0.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Eli Lilly and Company ($1.35T) is about 13,072.5 times ImmuCell ($103M), at today's prices.
Since November 16, 2016, ICCC's price moved +133.1% and LLY's +1,760.8%. With dividends: ICCC +133.1% (+8.8% a year), LLY +2,064.5% (+36.0% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for ImmuCell and 0.44% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.
At today's price, the P/E is 55.0 for ICCC and 49.0 for LLY. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 5.7% for ImmuCell and 31.9% for Eli Lilly and Company, and the operating margin 14.5% and –. Revenue was $33M and $86.5B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.